id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
inlawrev-18604	Wilcoxson, Maryn	A Lesson Learned from Myriad: The Affordable Care Act as Both an Incentive and an Alternative for Invalidating Stem Cell Patents	2014	32	.pdf	application/pdf	13356	672	56	[Vol. 48:723 possibility of stem cell patents being invalidated, the nonprofit group, Consumer Watchdog (“Watchdog”), has brought an appeal in the Federal Circuit challenging the patents on human embryonic stem cells (“hES cells”) held by the Wisconsin Alumni Research Foundation (“WARF”).7 Watchdog argues that under Myriad, these stem cells are products of nature and therefore are not patentable solely because they have been isolated.8 Part III analyzes what the United States stands to gain under the ACA from the invalidation of stem cell patents, including lowered costs for treatment of chronic conditions.	cache/inlawrev-18604.pdf	txt/inlawrev-18604.txt